Skip to content
Business Times – Lifestyle
Author:
Context Therapeutics Inc.
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
November 10, 2026
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
September 9, 2026
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
August 5, 2026
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
July 6, 2026
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
June 15, 2026
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 9, 2026
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
May 27, 2026
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 18, 2026